JP2020534284A - ワクチン、並びに、呼吸器合胞体ウイルス（ｒｓｖ）感染症を予防するためのワクチンの作製方法及び使用方法 - Google Patents

ワクチン、並びに、呼吸器合胞体ウイルス（ｒｓｖ）感染症を予防するためのワクチンの作製方法及び使用方法 Download PDF

Info

Publication number
JP2020534284A
JP2020534284A JP2020515680A JP2020515680A JP2020534284A JP 2020534284 A JP2020534284 A JP 2020534284A JP 2020515680 A JP2020515680 A JP 2020515680A JP 2020515680 A JP2020515680 A JP 2020515680A JP 2020534284 A JP2020534284 A JP 2020534284A
Authority
JP
Japan
Prior art keywords
rsv
protein
rvsv
composition according
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020515680A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534284A5 (enExample
Inventor
ステファン ニーウィスク
ステファン ニーウィスク
バサバラージ ビンジャワダジ
バサバラージ ビンジャワダジ
ジェンロン リ
ジェンロン リ
マーク ピープルズ
マーク ピープルズ
Original Assignee
オハイオ ステート イノベーション ファウンデーション
オハイオ ステート イノベーション ファウンデーション
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オハイオ ステート イノベーション ファウンデーション, オハイオ ステート イノベーション ファウンデーション, リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル, リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル filed Critical オハイオ ステート イノベーション ファウンデーション
Publication of JP2020534284A publication Critical patent/JP2020534284A/ja
Publication of JP2020534284A5 publication Critical patent/JP2020534284A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020515680A 2017-09-15 2018-09-14 ワクチン、並びに、呼吸器合胞体ウイルス（ｒｓｖ）感染症を予防するためのワクチンの作製方法及び使用方法 Pending JP2020534284A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762559167P 2017-09-15 2017-09-15
US62/559,167 2017-09-15
PCT/US2018/051054 WO2019055768A1 (en) 2017-09-15 2018-09-14 VACCINES AND METHODS OF MAKING AND USING VACCINES FOR THE PREVENTION OF SYNCYTIAL RESPIRATORY VIRUS (RSV) INFECTIONS

Publications (2)

Publication Number Publication Date
JP2020534284A true JP2020534284A (ja) 2020-11-26
JP2020534284A5 JP2020534284A5 (enExample) 2021-10-21

Family

ID=65723867

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020515680A Pending JP2020534284A (ja) 2017-09-15 2018-09-14 ワクチン、並びに、呼吸器合胞体ウイルス（ｒｓｖ）感染症を予防するためのワクチンの作製方法及び使用方法

Country Status (8)

Country Link
US (1) US20200276297A1 (enExample)
EP (1) EP3681523A4 (enExample)
JP (1) JP2020534284A (enExample)
KR (1) KR20200096904A (enExample)
CN (1) CN111344008A (enExample)
AU (1) AU2018331467A1 (enExample)
CA (1) CA3075990A1 (enExample)
WO (1) WO2019055768A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240113662A (ko) * 2023-01-13 2024-07-23 클립스비엔씨 주식회사 호흡기 신시치아 바이러스 변이체를 포함하는 호흡기 신시치아 바이러스 백신용 융합단백질 및 이의 제조방법
JP2024536236A (ja) * 2021-09-29 2024-10-04 エスケー バイオサイエンス カンパニー リミテッド 組み換えられた弱毒化ｒｓｖ生ワクチン及びその製造方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7657727B2 (ja) 2019-04-02 2025-04-07 サノフイ 抗原性多量体呼吸器合胞体ウイルスポリペプチド
CN112226450B (zh) * 2020-08-25 2022-10-14 北京交通大学 一种共表达呼吸道合胞病毒融合前蛋白和黏附糖蛋白的复制缺陷型腺病毒载体疫苗
CN118930654A (zh) * 2023-05-12 2024-11-12 中国科学院微生物研究所 一种呼吸道合胞病毒抗原制备方法和应用
CN117720628A (zh) * 2023-10-12 2024-03-19 中国科学院微生物研究所 一种呼吸道合胞病毒二价抗原制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247621A1 (en) * 2006-11-30 2010-09-30 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
JP2011507514A (ja) * 2007-12-20 2011-03-10 ワイス・エルエルシー Ｇタンパク質を発現する安定な細胞系を用いた、繁殖欠損水疱性口内炎ウイルスベクターをパッケージングする方法
JP2017523139A (ja) * 2014-06-13 2017-08-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組合せ物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1224462A (zh) * 1996-07-15 1999-07-28 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒呼吸道合胞病毒疫苗的方法
IL145797A0 (en) * 1999-04-13 2002-07-25 Government Of The Us Dept Of H Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences
AU2001264824A1 (en) * 2000-06-01 2001-12-11 St. Jude Children's Research Hospital Vaccine and gene therapy vector and methods of use thereof
US20050048030A1 (en) * 2001-09-28 2005-03-03 Raymond Pickles Paramyxoviruses as gene transfer vectors to lung cells
TWI344991B (en) * 2002-02-21 2011-07-11 Medimmune Vaccines Inc Metapneumovirus strains as vaccine formulations and as vectors for expression of heterologous antigenic sequences
EP1527087B2 (en) * 2002-07-26 2013-07-17 Her Majesty, The Queen in Right of Canada, as Represented by The Minister of Health Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers
WO2004113517A2 (en) * 2003-06-09 2004-12-29 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
US7585667B2 (en) * 2003-06-13 2009-09-08 The United States Of America As Represented By The Department Of Health And Human Services Negative strand RNA virus replicon
EP1756287B1 (en) * 2004-04-09 2015-02-25 Wyeth LLC Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
US20090092635A1 (en) * 2007-08-17 2009-04-09 Wyeth Heterologous prime-boost immunization regimen
BRPI0921424A2 (pt) * 2008-11-05 2016-01-05 Merck Sharp & Dohme vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica.
AU2015225553B2 (en) * 2014-03-01 2020-02-27 Profectus Biosciences, Inc. Recombinant Isfahan viral vectors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247621A1 (en) * 2006-11-30 2010-09-30 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
JP2011507514A (ja) * 2007-12-20 2011-03-10 ワイス・エルエルシー Ｇタンパク質を発現する安定な細胞系を用いた、繁殖欠損水疱性口内炎ウイルスベクターをパッケージングする方法
JP2017523139A (ja) * 2014-06-13 2017-08-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組合せ物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IMMUNOLOGY LETTERS, vol. 150, JPN6022030719, 2013, pages 134 - 144, ISSN: 0005012020 *
JOURNAL OF VIROLOGY, vol. 82, JPN6022030722, 2008, pages 12191 - 12204, ISSN: 0005012021 *
JOURNAL OF VIROLOGY, vol. 88, JPN6022030718, 2014, pages 5122 - 5137, ISSN: 0005012022 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024536236A (ja) * 2021-09-29 2024-10-04 エスケー バイオサイエンス カンパニー リミテッド 組み換えられた弱毒化ｒｓｖ生ワクチン及びその製造方法
KR20240113662A (ko) * 2023-01-13 2024-07-23 클립스비엔씨 주식회사 호흡기 신시치아 바이러스 변이체를 포함하는 호흡기 신시치아 바이러스 백신용 융합단백질 및 이의 제조방법
KR102806300B1 (ko) 2023-01-13 2025-05-14 클립스비엔씨 주식회사 호흡기 신시치아 바이러스 변이체를 포함하는 호흡기 신시치아 바이러스 백신용 융합단백질 및 이의 제조방법

Also Published As

Publication number Publication date
EP3681523A1 (en) 2020-07-22
WO2019055768A1 (en) 2019-03-21
CN111344008A (zh) 2020-06-26
US20200276297A1 (en) 2020-09-03
KR20200096904A (ko) 2020-08-14
CA3075990A1 (en) 2019-03-21
EP3681523A4 (en) 2021-12-29
AU2018331467A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
US11975067B2 (en) Coronavirus disease (COVID-19) vaccine
US20200276297A1 (en) Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
US9987353B2 (en) Virus like vesicles (VLVS) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection
JP2019510488A (ja) 抗腫瘍免疫を誘導するための、腫瘍関連抗原の複数のエピトープを発現するウイルスベクター
WO2022110099A1 (en) Coronavirus vaccines and uses thereof
WO2014132013A1 (en) Crimean-congo haemorrhagic fever virus antigenic composition
US20100068226A1 (en) Polynucleotides and Uses Thereof
US20210052718A1 (en) Respiratory syncytial virus (rsv) vaccines
US20240115693A1 (en) Sars-cov-2 antigen nanoparticles and uses there of
EP4210741A1 (en) Vaccine for viral pathogens
AU2022368453A1 (en) Chimeric betacoronavirus spike polypeptides
JP7801221B2 (ja) 流行性耳下腺炎ウイルスおよび麻疹ウイルスの免疫原およびそれらの使用
AU2012303887B2 (en) Use of the PACAP as a molecular adjuvant for vaccines
CN117599160A (zh) 狂犬病疫苗免疫原组合物
JP2003528614A (ja) 肝炎ウイルスのｏｒｆ２のｎ末端領域に由来するプロセシング成分および抗原性ポリペプチドをコードする核酸構築物
US12605443B2 (en) SAR-CoV-2 DNA vaccine and method of administering thereof
AU2021407771A1 (en) Coronavirus vaccine
HK40029686A (en) Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
JP2026065934A (ja) Ｓｎａｒｅを活用しウイルスに対する液性免疫を誘導する核酸構築物
JP2023024409A (ja) Ｓｎａｒｅを活用した核酸構築物
TW202406929A (zh) 多表位構築體
EP4282429A1 (en) Multivalent covid-19 vaccines based on adenoviral vectors
Allahverdiyev et al. Overview on under development of vaccine candidates against SARS-CoV-2
JPWO2005090576A1 (ja) 百日咳感染症予防用ｄｎａ構築物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210913

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230314